SOURCE: CancerVax

October 31, 2005 17:53 ET

CancerVax Corporation to Host Conference Call and Live Webcast to Discuss Third Quarter 2005 Financial Results

CARLSBAD, CA -- (MARKET WIRE) -- October 31, 2005 -- CancerVax Corporation (NASDAQ: CNVX), a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer, will host a conference call and live webcast on Monday, November 7, 2005 at 9:00 a.m. EST (6:00 a.m. PST) to discuss financial results for the third quarter ended September 30, 2005.

President and CEO David F. Hale will provide an update of the Company's pipeline of biological products for the treatment and control of cancer.

The conference call will be webcast simultaneously over the Internet. To listen, please visit the Investor Relations section of CancerVax's corporate web site at http://ir.cancervax.com. The webcast will be archived on this site for one year. Alternatively, callers may participate in the conference call by dialing (866) 700-0133 (domestic) or (617) 213-8831 (international). The passcode for the conference call is 54596924. A replay of the call can be accessed by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and the passcode is 16978767.

About CancerVax Corporation (www.cancervax.com)

CancerVax Corporation is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. CancerVax has a pipeline of product candidates and technologies that are being developed for the potential treatment of cancer. These include D93, CancerVax's lead anti-angiogenic, humanized, monoclonal antibody, and SAI-EGF, the Company's lead product candidate that targets the epidermal growth factor (EGF) receptor signaling pathway. CancerVax plans to file an Investigational New Drug (IND) application for clinical trials of D93 in early 2006, and to initiate a clinical trial with SAI-EGF in patients with advanced non-small-cell lung cancer in 2006.

Forward-Looking Statements

CancerVax Corporation

CancerVax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. For example, statements about the timing of the initiation of clinical trials with any of CancerVax's product candidates, and plans and objectives of management, are all forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation: the progress, timing and outcome of its clinical trials; its ability to obtain additional financing to support its operations, which could adversely affect its ability to continue to operate as a going concern; the risk that the collaboration agreement for Canvaxin™ may be terminated by Serono in certain instances; the risk that CancerVax may be required to pre-pay the debt incurred to expand its manufacturing capacity prior to the termination of the loan because of a failure to comply with covenants included in the loan agreement; unexpected adverse side effects or inadequate therapeutic efficacy of its product candidates that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; competition from other pharmaceutical or biotechnology companies; CancerVax's limited experience in manufacturing and testing biological products, which may result in delayed development or commercialization of its product candidates, as well as lost revenue; and other risks detailed in CancerVax's Securities and Exchange Commission filings, including CancerVax's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and Quarterly Report for the fiscal quarter ended June 30, 2005. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

CancerVax® is a registered trademark of CancerVax Corporation.

Canvaxin™ is a trademark of CancerVax Corporation.

Contact Information

  • William R. LaRue
    CancerVax Corporation
    SVP, CFO
    760-494-4200